RxDoctor Payments DataLook up a doctor →

Jose Fernandez Chavez, MD

Hematology & Oncology · Humacao, PRNPI 1972595668

Payments from drug & device makers

$694,478in general payments, 2019–2025

Across 450 payments — averaging $1543.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$684K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • AstraZeneca$984
  • Incyte Corporation$525
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$1,50514%
  • Food & beverage$8,51778%
  • Education$8708%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$694,478 in reported general payments places this provider in the 90th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$26,579
Medicare patients
39
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KeytrudaPembrolizumab74$875,981
RevlimidLenalidomide28$504,727
IbrancePalbociclib29$454,879
ErleadaApalutamide27$405,656
XtandiEnzalutamide22$323,912
Abiraterone Acetate113$197,472
Lenalidomide12$179,527
Everolimus19$132,323
XgevaDenosumab34$114,212
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres13$81,296
Exemestane42$12,328
XareltoRivaroxaban13$7,430
EliquisApixaban11$6,263
Bcg (Tice Strain)Bcg Live11$5,823
Ondansetron Hcl16$2,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckKeytruda$456$875,98174 claims
Bristol Myers SquibbRevlimid$521$504,72728 claims
PfizerIbrance, Eliquis$1,040$461,14240 claims
Johnson & JohnsonErleada, Xarelto$1,048$413,08640 claims
Astellas Pharma US IncXtandi$29$323,91222 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$34$197,472113 claims
AmgenXgeva$225$114,21234 claims
NovartisSandostatin Lar Depot$486$81,29613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →